ClinicalTrials.gg
Not yet recruitingNCT07940283Updated Nov 16, 2026

Effects of a Combination of Bifidobacterium Longum Subsp. Longum Strains on Stress and Related Health Outcomes in Young Adult

An interventional study of Bifidobacterium longum subspecies combination and Placebo in Psychological Stress and Mental Health, sponsored by DiproBio (Shanghai) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by DiproBio (Shanghai) Co., Ltd. · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies in Stress, Psychological with a site in China — 9 open to participants now, 11 under way, none of them phase 3. Stress, Psychological · China.

Planned enrollment
10th of 19
126 · median 126
Started
2026
with 3 others
No phase
18 of 28
4 open now
Primary completion
2027-06
later than 9 of 10 live
Registered
28th of 28
by date
Lead sponsor
1 of 28
DiproBio (Shanghai) Co., Ltd.

Among the 28 studies in Stress, Psychological with a site in China, this one is the 10th largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2026, is one of 18 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 28th registered.

Stress, Psychological

850 studies on the registry are indexed under Stress, Psychological; 139 are open to participants now.

Browse Stress, Psychological studies →

Open to participants now

9 of the 28 studies in Stress, Psychological with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 75 Stress, Psychological studies recruiting now, 34 (45%) set no upper age limit and 37 (49%) stop at 75 or younger; 14 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Stress, Psychological with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the effects of a combination of Bifidobacterium longum subsp. longum strains on stress-related health outcomes in adults. The study plans to enroll 126 adults experiencing stress-related problems, who will be randomly assigned in equal proportions to either the probiotic group or the placebo group and will receive the assigned intervention for 8 weeks. Participants will complete the scheduled study visits and assessments.

The study will systematically evaluate the principal health concerns of young adults experiencing high levels of stress through multiple approaches, including subjective questionnaire assessments, biological sample testing, and gut microbiome analysis. The main assessments will include a comparison of changes in stress status before and after the intervention between the probiotic and placebo groups using validated psychological assessment instruments. The effects of the intervention on sleep quality, quality of life, and related emotional states will also be evaluated. Sleep quality and quality of life will be assessed using validated assessment instruments.

To further investigate the potential biological mechanisms, stool samples will be collected from participants for gut microbiome metagenomic analysis to characterize changes in microbial composition and functional features. Laboratory-based assays will also be used to measure stress-, immune-, and inflammation-related biomarkers. This study is expected to provide preliminary evidence supporting the clinical application of microbiota-targeted interventions based on modulation of the gut-brain axis in populations experiencing high levels of stress.

03

Conditions studied

  • Psychological Stress
  • Mental Health
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18-65 years.
  2. Perceived Stress Scale-10 (PSS-10) score ≥ 14.
  3. Voluntary participation in the study and provision of written before any study procedures begin.

Exclusion criteria

Exclusion Criteria:

  1. Use of probiotic supplements or probiotic-containing products within 4 weeks before enrollment.
  2. Use of antibiotics or systemic within 4 weeks before enrollment.
  3. Current or previous diagnosis of psychiatric disorders (e.g., schizophrenia or major depressive disorder), epilepsy, major endocrine disorders, active inflammatory bowel disease or other severe gastrointestinal disorders, or severe sleep disturbances requiring treatment adjustment.
  4. Use of medications or dietary supplements that may affect the gut-brain axis, sleep, mood, or stress status assessment within 4 weeks before enrollment, including but not limited to sedative-hypnotics, anxiolytics, antidepressants, antipsychotics, mood stabilizers, and supplements with sleep-inducing, sedative, or stress-relieving effects (e.g., magnesium-containing supplements).
  5. Pregnant or breastfeeding women.
  6. Known allergy to the study product or any of its components.
  7. Smoking or alcohol consumption on the day of the study visit or within 48 hours before the visit.
  8. Participation in other clinical intervention studies involving drugs, dietary supplements, probiotics, or prebiotics within the past 3 months.
  9. Insufficient compliance, as judged by the investigator, to complete sample collection or study-related documentation as required by the study protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Probiotic group

    Participants receive Bifidobacterium longum subspecies combination formulation.

    Dietary Supplement: Bifidobacterium longum subspecies combination

  • Placebo comparator
    Placebo group

    Participants receive a matching placebo formulation.

    Other: Placebo

Interventions

  • Dietary supplementBifidobacterium longum subspecies combination

    Participants receive an oral probiotic combination formulation according to the study protocol for the duration of the intervention.

  • OtherPlacebo

    Participants receive a matching placebo formulation according to the same administration schedule as the probiotic intervention.

06

What researchers measure

Primary outcomes

  1. Depression Anxiety Stress Scales-42 (DASS-42) Stress Subscale Score

    Stress levels will be assessed using the Stress subscale of the 42-item Depression Anxiety Stress Scales (DASS-42). The subscale consists of 14 items, each scored from 0 to 3. The total Stress subscale score ranges from 0 to 42, with higher scores indicating greater stress severity. Raw scores will be reported at each assessment time point.

    Time frame: Baseline, Week 4, Week 8

Secondary outcomes

  1. Pittsburgh Sleep Quality Index (PSQI) Global Score

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The global score is calculated by summing seven component scores, each ranging from 0 to 3. The total global score ranges from 0 to 21, with higher scores indicating poorer sleep quality. Raw PSQI global scores will be reported at each assessment time point.

    Time frame: Baseline, Week 4, Week 8

  2. WHOQOL-BREF Physical Health Domain Score

    Quality of life in the physical health domain will be assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire. Domain scores will be transformed to a scale ranging from 0 to 100, with higher scores indicating better quality of life in the corresponding domain. Raw transformed domain scores will be reported at each assessment time point.

    Time frame: Baseline, Week 4, Week 8

  3. Relative Abundance of Prespecified Gut Microbial Taxa

    The relative abundance of prespecified gut microbial taxa will be assessed using shotgun metagenomic sequencing of fecal samples. Relative abundance will be expressed as a percentage of the total taxonomic abundance assigned to the selected taxa at each assessment time point.

    Time frame: Baseline, Week 4, Week 8

  4. Gut stress and immune biomarkers

    Time frame: Baseline, Week 4, Week 8

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.

Of 472 interventional studies with no phase under Stress, Psychological, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 16, 2026
StartEst.
Nov 9, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940283
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 9, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Yuan Jie
Contact
peanut.yuan@diprobio.com
+86 198 2187 2781

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion